Abdeahad Hossein, Saeedi Nikoo, Bahrami Afsane, Mohammed Al-Asady Abdulridha, Mansoori Saeide, Avan Amir, Khazaei Majid, Ghorbani Elnaz, Ryzhikov Mikhail, Hassanian Seyed Mahdi
Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Equal first author.
Avicenna J Phytomed. 2024 May-Jun;14(3):297-304. doi: 10.22038/AJP.2023.23175.
Radiodermatitis (RD) is a frequent adverse event of radiotherapy (RT). Currently, there is no consensus and approved protocol for the treatment of RD. Curcumin (CUR) is a natural polyphenol obtained from turmeric and it has low intrinsic toxicity in humans. The aim of this systematic review was to explore the efficacy of CUR for prevention and treatment of RD.
A systematic literature review was performed in the following online databases: Cochrane library, PubMed, Scopus, Web of Science, MEDLINE, and EMBASE. Among the 5 selected records, 3 had a randomized clinical trial (RCT)-design and the other had a pilot and controlled study designed. The included studies were performed on breast cancer (N=3), head and neck cancers (N=1) and different types of cancer (N=1).
Four of the studies reported that the application of curcumin in cancer patients undergoing radiotherapy is associated with decreased intensity of radiodermatitis. However, one study did not report any significant effect of CUR on radiodermatitis. This review provides substantial evidence which confirm the clinical value of CUR in cancer supportive care.
Further prospective clinical trials in larger scales are warranted in order to determine the " supplemental form and dose of CUR" for RD prevention and treatment in patients receiving radiotherapy.
放射性皮炎（RD）是放射治疗（RT）常见的不良事件。目前，对于放射性皮炎的治疗尚无共识和批准的方案。姜黄素（CUR）是从姜黄中提取的天然多酚，对人体的内在毒性较低。本系统评价的目的是探讨姜黄素预防和治疗放射性皮炎的疗效。
在以下在线数据库进行系统文献回顾：Cochrane图书馆、PubMed、Scopus、科学网、MEDLINE和EMBASE。在筛选出的5篇记录中，3篇采用随机临床试验（RCT）设计，另外1篇采用试点对照研究设计。纳入研究的对象为乳腺癌患者（n = 3）、头颈癌患者（n = 1）和不同类型癌症患者（n = 1）。
4项研究报告称，在接受放疗的癌症患者中应用姜黄素与放射性皮炎强度降低有关。然而，1项研究未报告姜黄素对放射性皮炎有任何显著影响。本综述提供了大量证据，证实了姜黄素在癌症支持治疗中的临床价值。
有必要开展进一步的大规模前瞻性临床试验，以确定接受放疗患者预防和治疗放射性皮炎时姜黄素的“补充形式和剂量”。
